To speak of reasons to “buy” is to reduce the matter to a crude transaction. It is as if one were to quantify the turning of the seasons. Still, the currents flow, and one must acknowledge their direction. Let us consider, then, not reasons for acquisition, but observations of a certain… solidity, a certain momentum within this enterprise.
They’ve acquired a respectable 137,768 shares, which, when one adds it all up, represents a touch under two percent of Palisades’ rather handsome portfolio. Not a vast sum, perhaps, but enough to suggest they aren’t simply rearranging the deckchairs on the Titanic. The shares were, at the quarter’s end, worth the same five and a quarter million, a rather pleasing coincidence, what!
Here, the duo slices through the typical “speculative asset” patina, presenting crypto as the unsung infrastructure poised to counter ever‑growing AI centralisation, offering users command over their own data, their digital selves, and their economic destiny.
To predict its trajectory over the next three years is, of course, an exercise in controlled illusion. The future, as any student of the Kabbalah will tell you, is a labyrinth of branching possibilities. Yet, within that labyrinth, certain paths exhibit a peculiar persistence. Coca-Cola, I suspect, occupies one of those paths.
Today, ETH tiptoes around $2,957 to $2,960, like a cat walking the windowsill-close enough to feel the allure of $3K but not quite brave enough to leap. A fleeting glance above that magical threshold was met with a quick retreat, as if the market was reminding us, “Hey, patience is a virtue, or so my trading bot keeps telling me.”
SPDW, one observes, manages to offer a lower expense ratio while simultaneously exhibiting a superior dividend yield and one-year return. A rather neat trick, wouldn’t you say? VWO, however, possesses a significantly larger AUM, which, while not necessarily indicative of performance, does suggest a certain degree of popularity. Or perhaps simply inertia.
Now, the numbers themselves weren’t bad. Revenue was $12.05 billion, up 18% year over year. They beat estimates. Net income climbed 29% to $2.4 billion. Basically, they made a lot of money. But Wall Street is a demanding mistress. It’s never enough. It’s like being a contestant on a cooking show – you can make a perfect soufflé, but the judges are still going to find something to critique, probably the garnish.
After sailing through phase 3 trials with a commendable lack of fuss, Eli Lilly had submitted its application for orforglipron in December. The FDA, in a rather sporting gesture, granted the application a voucher allowing for a swift review – a month or two, as opposed to the usual year-long wait. A decision by the end of February seemed entirely reasonable, and investors were, naturally, anticipating a prompt resolution. However, the FDA, in a display of bureaucratic caution, has now extended the review period until April 10th. A dashedly annoying turn of events, what!
The market, in its perpetual state of agitation, has seen fit to offer this rather substantial concern at a discount. A fleeting weakness, perhaps, or merely a demonstration of its own capricious nature. But let us not mistake temporary displeasure for fundamental flaw. Brookfield, you see, is not a stock for those who chase fleeting fancies. It is an investment for those who understand that true wealth is built not on speculation, but on the solid foundations of enduring assets.
Now, it’s suddenly a star. Included in the S&P 500. Doubled year-to-date. Of course. Because now everyone notices. It’s the principle of the thing. You spend decades being perfectly adequate, then suddenly you’re a genius. It’s like waiting thirty years for a table at a restaurant, and then they finally call your name and the food is just… okay. Just okay! What was the point?